Trial Profile
A Multiple-Ascending Dose Study in Japanese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Tirzepatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company (India) Pvt. Ltd; Eli Lilly Japan
- 16 Jun 2020 Results assessing effects of Tirzepatide on Meal Intake and Appetite in Japanese Patients with Type 2 Diabetes presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 08 Jun 2019 Results published in the Eli Lilly Media Release.